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propofol in critically ill patients, and subsequently determining the best strategy 
for administering propofol. Methods: Costs of propofol-related infection and the 
different strategies of administration of propofol were computed according to the 
literature and microcosting method. The additional length of stay in ICU due to 
major infections related to propofol administration was estimated using the disabil-
ity model, assuming a cost of CHF 2’118/intensive care unit day (local cost). The cost 
of each strategy was estimated based on all costs and on the probability of major 
infections related to propofol administration. Results: According to the links 
found in the literature by genotyping bacteria (syringe-patient), we assumed that a 
patient has a mean 22.6% risk of developing an infection by a contaminated prepa-
ration of propofol. Thus, the ready-to-use syringe and syringes drawn from vials 
have an infection probability of 0.0014 [0.0009 – 0.0038] and 0.0118 [0.0056 – 0.0181] 
respectively. Probability of infection and the extended length of stay were the cost-
drivers of this analysis. Ready-to-use syringes of propofol saved money, decreasing 
the cost by at least CHF 251 per sedation. Ready-to-use syringes remained a cost 
saving strategy when the propofol related infection rate probability according to the 
literature was as high as 0.38%. ConClusions: Ready-to-use syringes of propofol 
save money by preventing major infections related to its administration.
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objeCtives: Averting 20% of new HIV infections, the country has to achieve 80% 
national circumcision coverage. Given the inadequacy of human resource at cir-
cumcision centers in Uganda, we conducted a study to assess the cost-effectiveness 
of PrePex device (none surgical) and Dorsal-slit technique (surgical) for scaling-up 
adult safe medical male circumcision. Methods: In a four weeks cost effective-
ness course project during November 2012, we modeled the costs and effects of 
male circumcision of the 2 commonest strategies (Dorsal-slit technique as standard 
and PrePex device) used in Uganda. Effectiveness was defined as days of complete 
healing measured by costs from start of procedure to complete healing. This was 
the time until end of each procedure when all scores for drainage from incision, 
epithelialization, granulation of tissue, and edema were zero. We estimated costs 
and effects from previous studies in developing countries. Direct and indirect costs 
were included in a cost effectiveness analysis with limited government perspective. 
Costs for demand creation (training, patient counseling, and promotion campaigns) 
were excluded. One-way sensitivity analysis was done by varying costs and days of 
complete healing as main model parameters. Analyses were done using TreeAge 
Pro-2011 software. Results: PrePex (none surgical) utilized $52.13 over the days 
to complete healing (31 days) compared to dorsal-slit (surgical) utilizing $67.8 over 
the days to complete healing (23 days). PrePex was less costly ($52) and with lowest 
adverse-events (0.98) compared to dorsal-slit technique 0.96 adverse-events cost-
ing $65.9. PrePex device was mostly not sensitive to changes in costs and days to 
complete healing. ConClusions: PrePex device was cost-saving and cost effective.
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objeCtives: Two major clinical trials examined the efficacy of caspofungin (CAS) 
and voriconazole (VORI) for empiric therapy of febrile neutropaenia (FN). We inves-
tigated the cost-effectiveness of empiric CAS vs. VORI in FN from the Turkish per-
spective. Methods: The downstream consequences of CAS or VORI were captured 
through decision tree analysis. Outcome measures included success, breakthrough 
fungal infection, persistent base-line fungal infection, persistent fever, premature 
discontinuation and death. Probability data were extracted from the major stud-
ies. An expert panel estimated health care resource consumption and alternative 
treatment after initial failure with either agent. Cost was based on 2012 data using 
Turkish Lira (TL). Deterministic and probabilistic sensitivity analyses were per-
formed. Results: Compared to VORI, CAS was dominant by TL2,533, TL29,256 and 
TL2,536 per patient treated, successfully treated and patient survival, respectively 
(approx. USD1,414, 16,328 and 1,415). CAS had a higher likelihood of success and 
lower mortality than VOR (34.17% vs. 26.02% and 7.37% vs. 7.95%, respectively). 
Increasing the list cost or length of stay (LOS) for CAS by > 35% or 1.3 days, respec-
tively, changes the study outcomes. A decrease of list cost or LOS for VOR by > 32% 
or 1.2 days resulted in it being favorable. Removing fever resolution as part of the 
composite outcome afforded a contracted difference (CAS preferred by TL298 and 
299 per patient treated and surviving with VORI preferred by TL488 per patient 
successfully treated). Monte Carlo simulation of 10,000 subjects, with variability 
imputed on the outcome probabilities taken from the literature, LOS and hospitali-
sation costs, resulted in a 78.8% chance of favoring CAS. ConClusions: There is 
a high likelihood of CAS being cost-effective compared to VORI in the treatment of 
FN in Turkey. Sensitivity analyses highlighted a robust advantage towards CAS. The 
model is moderately sensitive to changes in LOS or cost of each agent.
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using the constant discounting approach. The empirical , hyperbolic and propor-
tional discounting methods provided ICERs three times higher. The time-shifted and 
stepwise discounting led to favorable ICERs that were much below the NICE thresh-
old. ConClusions: The use of different discounting approaches had a considerable 
effect on the cost-effectiveness results. For preventive programs and vaccines con-
stant discounting approach was unfavorable since the health benefits are revealed 
decades later. Constant discounting could not justify the theory of social and indi-
vidual time preference. The empirical discounting though discounted the outcomes 
at a much slower rate in the long term; the approach remained unfavorable owing to 
the heavy discounting in the short term. The time-shifted and stepwise discounting 
were feasible for the vaccines as they related to the moment of risk reduction and 
were persistent with the time-preference theory, respectively.
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objeCtives: A pivotal clinical trial failed to demonstrate non-inferiority of voricona-
zole (VORI) vs. liposomal amphotericin B (LAMB) for empiric treatment of febrile neu-
tropaenia (FN). This study investigated the cost-effectiveness of the two options from 
the Turkish health care system’s perspective. Methods: A decision-tree analysis 
was used to capture downstream consequences of each agent. Outcome measures 
included success, breakthrough fungal infection, persistent base-line fungal infection, 
persistent fever, premature discontinuation and death. Probability data were extracted 
from the published clinical trial. Resource consumption and alternative treatment 
after initial failure with either agent were estimated by an expert panel. Cost was 
based on 2012 data within Turkey. Deterministic and probabilistic sensitivity analyses 
were performed to determine the model’s robustness. Results: Compared to LAMB, 
VORI was the cost-effective alternative per patient treated and per patient survival 
(by TL2,523 (approx USD1,396) and TL2,520 (approx USD1,394), respectively). LAMB 
was preferred when considering the cost per successfully treated patient (TL5,362 
difference in favor of LAMB, approx USD2,966). LAMB had a higher likelihood of suc-
cess (30.57% vs. 26.02%) and lower probability of death than VORI (5.92% vs. 7.95%). 
Increasing the list cost or length of stay (LOS) of VORI by > 32.4% or 1.2 days, respec-
tively, changes the study outcomes. Decreasing list cost or LOS for LAMB by > 15.8% 
or 1.0 days, respectively, resulted in LAMB becoming favorable. Monte Carlo simula-
tion (MCS) of 10,000 subjects, with variability imputed upon the published outcome 
probabilities, LOS and hospitalization costs, resulted in a 69.4% chance of favoring 
VORI. ConClusions: VORI appears to be cost-effective when compared to LAMB in 
the empiric treatment of FN from the Turkish perspective. One-way sensitivity analy-
ses did not change the conclusion with MCS indicating a 69.4% chance of favoring 
VORI. The outcome was highly sensitive to list cost and LOS.
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objeCtives: Catheter-related bloodstream infection (CRBSI) is a frequent (1-5/1000 
catheter-days) and life-threatening complication in intensive care unit (ICU), pre-
ventable by systematic use of a new antimicrobial transparent dressing containing 
a chlorhexidine gluconate (CHG) hydrogel (60% risk reduction in a recent RCT). Our 
purpose is to evaluate the advantages of routine use of the new CHG-dressing to 
secure central lines of patients in ICU from the medico-economic viewpoint compared 
to non-antimicrobial (reference). Both medical and economic criteria are embedded 
into an analytic decision model to support the choice of the best dressing strat-
egy. Methods: A 30-day ICU-time non-homogeneous markovian model comprises 
eight states: five combining either occurrence or no-occurrence of: CRBSI, contact 
dermatitis, and the need of a new central line; one for changing alternative dressing 
in case of dermatitis and two absorbent states (death and discharge). The probabili-
ties of events derive a multicentre RCT on 1,879 patients. Monte Carlo simulations 
of 1,000 patients are used for probabilistic sensitivity analysis and 95% confidence 
intervals (CI) calculations. The final health outcome is the number of CRBSI averted. 
Costs of ICU stay are updated from estimations of a French study from 2010. This 
economic evaluation takes into account ICU perspective in France. Results: The 
CHG-dressing prevents 11.75 infections (95% CI: [-19.64; -3.85], number needed to 
treat= 85) for 1,000 patients as estimated via probabilistic cost-effectiveness sensitivity 
analysis. The mean adjusted cost per patient is € 2013 21,391 [95% CI: € 20,339; € 22,443] 
for the CHG-dressing group and € 2013 20,882 [95% CI: € 19,905; € 21,859] for the reference 
dressing. ConClusions: The CHG-dressing, significantly more efficacious to prevent 
CRBSI when compared to the reference dressing, contributes to preserve patients’ 
health capital at the same cost for the ICU. According to the base case scenario the 
CHG-dressing is more cost-effective than the reference dressing.
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objeCtives: Primary nosocomial bloodstream infections (BSI) (5-15% of all infec-
tions) are associated with increased length of stay and additional hospital costs. 
Propofol infusions, commonly used for sedation in intensive care units (ICU), are 
formulated in lipid emulsion which promotes microbial growth. The present study 
aimed at identifying the probabilities and costs of contamination of syringes of 
